Harnessing the prognostic power of preoperative systemic immuneinflammation index/albumin ratio in hepatocellular carcinoma resection  

作　　者：Zhao-Nan Zhang Liang Hao Shuang Han Shan-Shan Li Si-Xiang Lin Yan-Dong Miao 

机构地区：[1]Cancer Center,Yantai Affiliated Hospital of Binzhou Medical University,The 2nd Medical College of Binzhou Medical University,Yantai 264100,Shandong Province,China

出　　处：《World Journal of Gastrointestinal Surgery》2025年第2期320-324,共5页世界胃肠外科杂志(英文)

基　　金：Supported by Shandong Province Medical and Health Science and Technology Development Plan Project,No.202203030713;Science and Technology Program of Yantai Affiliated Hospital of Binzhou Medical University,No.YTFY2022KYQD06.

摘　　要：The recent study by Chen et al,published in the World Journal of Gastroenterology,introduces a groundbreaking assessment tool-the preoperative systemic immuneinflammation index/albumin(SII/ALB)ratio-for patients with hepatocellular carcinoma(HCC)undergoing curative resection.This study not only establishes the independent prognostic significance of the SII/ALB ratio but also incorporates it into a predictive nomogram,enhancing its utility for clinical decision-making.The SII/ALB ratio,by integrating inflammatory and nutritional biomarkers,offers a novel lens through which the prognosis of HCC patients can be viewed,suggesting a more tailored approach to patient management.The development of the nomogram,validated for its accuracy in predicting patient outcomes,marks a pivotal advance,potentially guiding surgical decisions and postoperative care.However,the study's focus on a single-center cohort prompts the need for validation in a broader,more diverse patient population to ensure its applicability across various clinical settings.Moreover,longitudinal studies could elucidate the dynamic changes in SII/ALB post-surgery,offering insights into its potential as a continuous monitor for recurrence and long-term survival.This abstract aim to underscore the critical findings of Chen et al's study while calling for further research to explore the full potential of the SII/ALB ratio in the global management of hepatocellular carcinoma.

关 键 词：Hepatocellular carcinoma Inflammation Hepatocellular carcinoma resection 

分 类 号：R735.7[医药卫生—肿瘤]